$ZLAB

Lis William sold $127K of ZLAB

Lis William sold 7,040 shares of Zai Lab Ltd (ZLAB) at $18.09 ($0.13M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lis William
Published Jun 24, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ZLAB
Neutral
high confidence
Mentioned
$ZLAB
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZLABNeutralLow
01

Why it matters

The disclosed sale can marginally influence short-term sentiment, but the 10b5-1 pre-arrangement generally lowers the informational content for fundamental repricing.

02

Market read

Traders may monitor for follow-on insider activity, but this specific transaction is unlikely to drive a material repricing.

03

What to watch

The filing does not disclose intent beyond the plan; without additional context (e.g., other insider buys/sales around the same window), the signal is limited.

Relevance 3/10Novelty 5/10Timing: after-hours/filing date (2026-06-24) for a 2026-06-22 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Zai Lab Ltd, reporting a director’s open-market sale.

Company-level read

Ticker impact

$ZLABNeutralHigh confidence
Context

SEC Form 4 shows director Lis William sold 7,040 Zai Lab shares on 2026-06-22 under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale by a director with an explicitly pre-arranged 10b5-1 plan, which typically reduces signaling risk versus discretionary selling.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so traders may ignore it.

Key entities

  • Zai Lab Ltd

    Company whose shares were sold by a director under a 10b5-1 plan.

  • Lis William

    Director who executed the reported open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ZLABMedAI 9/10

How Investors Are Reacting To Zai Lab (ZLAB) Phase 3 VYVGART Hytrulo Autoimmune Myositis Data

Zai Lab (ZLAB) and Argenx reported positive Phase 3 results for VYVGART Hytrulo in treating autoimmune myositis, showing significant improvements over placebo. The data suggest potential for the drug in a market currently dominated by corticosteroids. Analysts highlight the importance of execution on recent launches and China's pricing pressures. Some analysts predict modest revenue growth and continued losses by 2029.

$ARGXMedAI 9/10

Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?

Argenx (ARGX) and Zai Lab (ZLAB) reported positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. ARGX saw a 15% stock rise and a $1,100 price target from RBC. ARGX reported Q2 2026 revenue of $1.516B, up 60% YoY, while ZLAB reported $106.3M revenue, down 3% YoY. ARGX has a stronger financial position with $5.2B in cash, while ZLAB has $717.5M. Investors should watch FDA decisions and ZLAB's commercial execution.

$ZLABMedAI 8/10

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Zai Lab (NASDAQ: ZLAB) and argenx (NASDAQ: ARGX) reported positive topline Phase 3 ALKIVIA results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis. The study met the Week 52 primary endpoint in the combined IMNM and DM population (p=0.0011), with mean Total Improvement Score 47.95 vs 32.56 vs placebo. IMNM also met (p=0.0048); DM did not reach significance (p=0.1093).

$ZLABMedAI 8/10

Zai Lab, argenx report positive Phase 3 ALKIVIA results

Zai Lab and argenx reported positive Phase 3 ALKIVIA results for VYVGART Hytrulo (efgartigimod). At Week 52, mean TIS improved 15.4 points more than placebo (p=0.0011), with benefits starting by Week 4 and persisting through one year despite steroid tapering. Zai Lab shares were about 0.3% lower premarket at $25.90.

$ZLABMedAI 8/10

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

Zai Lab (ZLAB) reported Q2 2026 revenues of $106.3 million, down from $110.0 million a year earlier. Net product revenue was $105.8 million, up 11% sequentially, with growth tied to VYVGART and stabilization of ZEJULA. Net loss was $50.8 million ($0.05/share). Cash was $717.5 million at June 30, 2026. Management discussed Zoci and VYVGART timelines and supply constraints.

$ZLABMed

Zai Lab Q2 Earnings Call Highlights

Zai Lab (NASDAQ:ZLAB) said it plans to seek China NRDL inclusion for VYVGART HYTRULO and shift the VYVGART franchise from IV to subcutaneous. Management flagged timing effects on second-half revenue, aims to stabilize revenue before stronger 2027 growth, and reported $717.5M cash. It outlined zoci ADC Phase III plans and pipeline updates.